PLEASE NOTE FOLKS,the caveat:
I looked at the study from Dr. Didier Raoult ( the first and second one he published, the second study with 80 patients ).
The advantage of hydroxychloroqine is its potential reduction in length of stay of Covid-19 positive patients who are not that severely ill, reducing the burden on the hospitals. THIS IS STILL SIGNIFICANT!
But I also want to see lives saved !
I hope it also helps in significant reduction in mortality (especially for the very ill, e.g. on ventilators ), but widespread usage still needs to prove that.
That’s a huge promise - cutting the mean length of stay in the ICU from 12 to 6 days, and reducing the severity overall will be an enormous time, money, and life-saver.